Lidocaine

證據等級: L5

預測適應症: 10 個

Lidocaine: From Local Anesthesia to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Lidocaine is an amide-type local anesthetic long used for topical, infiltrative, and regional anesthesia (including routine use during ophthalmic procedures). The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but currently 0 clinical trials and 0 publications support this direction, and the underlying mechanism plausibly points the opposite way.

Quick Overview

Item	Content
Original Indication	Local anesthesia (topical/infiltrative/regional) — no formal indication text available in this evidence pack
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.99% (rank 692 of model output)
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (Data Gap DG002, High severity). Based on known pharmacology, lidocaine is a voltage-gated sodium channel blocker used clinically as a local anesthetic and, in ophthalmology, as an off-label anesthetic agent for procedures such as subconjunctival and intravitreal injections, pterygium excision, and peribulbar blocks — as reflected by the many procedural trials found elsewhere in this evidence pack for other candidate indications.

For punctate epithelial keratoconjunctivitis specifically, however, the evidence pack contains no clinical trials or literature connecting lidocaine to this indication. The model’s rationale itself flags a mechanistic concern rather than support: prolonged or inappropriate topical anesthetic use is a known risk factor for corneal epithelial toxicity, which is the opposite of a therapeutic effect on epithelial keratoconjunctivitis. In other words, the pharmacological direction implied by known lidocaine toxicity data runs counter to the predicted new indication, rather than reinforcing it.

Given this, the high TxGNN score should be treated as a model-driven signal only, not as evidence of a plausible therapeutic mechanism.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No FDA/regulatory market authorization records are present in this evidence pack — market status is recorded as Not Marketed, with 0 licenses/NDAs on file. (Note: lidocaine is widely marketed globally under other regulatory pathways/products; this evidence pack simply contains no license records to cite.)

Safety Considerations

Please refer to the package insert for safety information.

(Note: Data Gap DG001 — TFDA label warnings/contraindications — is classified as Blocking, meaning this candidate cannot pass initial safety screening (S1) until label data is obtained.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is supported only by a TxGNN model score (L5, decision stage S0), with zero clinical trials or literature specific to punctate epithelial keratoconjunctivitis. The available mechanistic reasoning suggests a potential safety concern (corneal epithelial toxicity from anesthetic overexposure) rather than a therapeutic rationale, so this is not just low-evidence but potentially direction-reversed.

To proceed, the following is needed:

TFDA label warnings/contraindications for lidocaine (Blocking data gap DG001) before any S1 safety screening
Confirmed mechanism of action data (DG002) to properly assess mechanistic plausibility
Primary literature or preclinical studies directly evaluating lidocaine in punctate epithelial keratoconjunctivitis or comparable corneal epithelial pathology
Given the corneal toxicity signal, an explicit safety review before considering any further work on this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.